Heart failure - Epidemy of the 21st century;Srdeční selhání - Epidémie 21. století

Vnitrni Lekarstvi

Volumn 50, Issue SUPPL. 1, 2004, Pages

  Hradec, Jaromír ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Epidemiology; Heart failure; Prognosis; Treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE HEART INFARCTION; AGING; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIOVASCULAR DISEASE; CELL BASED GENE THERAPY; CLINICAL TRIAL; CZECH REPUBLIC; DEFIBRILLATOR; DEVELOPED COUNTRY; DEVICE; GENE TECHNOLOGY; HEART FAILURE; HUMAN; INCIDENCE; LIFE EXPECTANCY; MORTALITY; PREVALENCE; PROGNOSIS; STROKE; AGED; CONGESTIVE HEART FAILURE; FEMALE; MALE; MIDDLE AGED;

AGED; AGED, 80 AND OVER; CZECH REPUBLIC; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS;

EID: 9244249784     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. American Heart Association, Dallas 2002.
2. Zdravotnická ročenka 2002. Praha: ÚZIS 2003.
3. Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853.
4. Banerjee P, Banerjee T, Khand A et al. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol 2002; 105: 1304-1310.
5. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail 2001; 3: 283-291.
6. Brutsaert DL, Sys SU. Diastolic dysfunction in heart failure. J Card Fail 1997; 3: 225-242.
7. Cleland JG. Kongres AHA 2004, New Orleans, USA.
8. Dries DL, Strong MH, Cooper RS et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction in symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002; 40: 311-317.
9. European Study Group on Diastolic Heart Failure: How to diagnose diastolic heart failure. Eur Heart J 1998; 19: 990-1003.
10. Haldeman GA, Croft JB, Giles WH et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J 1999; 137: 352-360.
11. Ho KK, Pinsky JL, Kannel WB et al. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 (Suppl. 4A): 6A-13A.
12. Hradec J. Diastolické srdeční selhání. Remedia 2004; 14: 121-125.
13. Hunt SA, Baker DW, Chin MH et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 2001; 104: 2996-3007.
14. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951-957.
15. Khand A, Gemmel I, Clark AL et al. Is the prognosis of heart failure improving? J Am Coll Cardiol 2000; 36: 2284-2286.
16. Kitzman DW, Gardin LM, Gottdiener JS et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 2001; 87: 413-419.
17. Komajda M, Follath F, Swedberg K et al. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euro Heart Failure Survey Programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: Treatment. Eur Heart J 2003; 24: 464-475.
18. Konstam MA. Progress in heart failure management? Lessons from the real world. Circulation 2000; 102: 1076-1078.
19. Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402.
20. Massie BM, Teerlink JR. Interaction between aspirin and angiotensin-converting enzyme inhibitors: real or imagined? Am J Med 2000; 109: 431-433.
21. Moss AJ, Zareba W, Hall WJ et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
22. O'Connell JB. The economic burden of heart failure. Clin Cardiol 2000; 23 (Suppl. 3): III6-III10.
23. Remme WJ, Swedberg K (for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology). Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
24. Saxon LA, De Marco T. Cardiac resynchronization: a cornerstone in the foundation of device therapy for heart failure. J Am Coll Cardiol 2001; 38: 1971-1973.
25. Senni M, Redfield MM. Heart failure wich preserved systolic function: a different natural history? J Am Coll Cardiol 2001; 38: 1277-1282.
26. Schaufelberger M, Swedberg K, Köster M et al. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden. Data from Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J, 2004; 25: 300-307.
27. Špaček R, Widimský P. Infarkt myokardu. 1. vyd. Praha: Galén 2003.
28. Špinar J, Hradec J, Málek I et al. Doporučení pro diagnostiku a léčbu chronického srdeční ho selhání. Cor Vasa 2001; 43: K123-K137.
29. Widimský J, Lánská V, Magulová D et al. Průzkum stavu aktuální praxe diagnostiky a léčby srdečního selhání v ordinacích všeobecných lékařů v České a Slovenské republice v roce 1999. 2. část programu IMPROVEMENT of HF. Cor Vasa 2001; 43: 345-352.
30. Widimský J et al. Srdeční selhání. 3. vyd. Praha: Triton 2001.
31. Wilhemsen L, Rosengren A, Eriksson H et al. Heart failure in the general population of men-morbidity, risk factors and prognosis. J Intern Med 2001; 249: 253-261.
32. Yusuf S, Pfeffer MS, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781.